Vismodegib Shows Activity Against Adult Recurrent SHH-Medulloblastoma

Share this content:
Vismodegib exhibits activity against adult recurrent SHH-medulloblastoma.
Vismodegib exhibits activity against adult recurrent SHH-medulloblastoma.

Vismodegib exhibits activity against adult recurrent sonic hedgehog (SHH)-medulloblastoma but not against recurrent non-SHH medulloblastoma, a new study published online ahead of print in the Journal of Clinical Oncology has shown.

Researchers analyzed results from two phase 2 studies that assessed the efficacy of vismodegib, a SHH pathway inhibitor, in pediatric and adult patients with recurrent medulloblastoma.

Researchers enrolled 31 adult patients and 12 pediatric patients. All patients were treated with vismodegib 150 to 300 mg/day.

Results showed that three adult patients and one pediatric patient, all with SHH-subgroup medulloblastoma, achieved a sustained response for 8 weeks. Researchers found that progression-free survival was longer in patients with SHH-subgroup medulloblastoma compared with those with non-SHH-medulloblastoma.

RELATED: Bevacizumab May Add Survival Benefit for Wild-Type Proneural Glioblastoma

The study also demonstrated that among those with SHH-medulloblastoma, loss of heterozygosity of PTCH1 was associated with prolonged progression-free survival, while diffuse staining of p53 was linked with reduced progression-free survival.

The findings suggest that further research is warranted to identify patients with certain genomic aberrations that will benefit the most.

Reference

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters